Evidence map›Paper›PMID 30241184›Full record

ArticleJournal of global oncology2018

Comparison of Receptor-Defined Breast Cancer Subtypes Between German and Sudanese Women: A Facility-Based Cohort Study.

Asmerom Tesfamariam Sengal, Nada Suliman Haj Mukhtar, Martina Vetter, Ahmed Mohammed Elhaj, Shahinaz Bedri, Steffen Hauptmann, Christoph Thomssen, Ahmed Abdalla Mohamedani, Claudia Wickenhauser, Eva Johanna Kantelhardt

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of global oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Intrinsic subtypes in Ethiopian breast cancer patient.Breast cancer research and treatment · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Asmerom Tesfamariam SengalAsmerom Tesfamariam Sengal, Nada Suliman Haj Mukhtar, Ahmed Mohammed Elhaj, and Ahmed Abdalla Mohamedani, University of Gezira, Gezira, Sudan; Asmerom Tesfamariam Sengal, Orotta School of Medicine and Dentistry, Asmara, Eritrea; Martina Vetter, Christoph Thomssen, Claudia Wickenhauser, and Eva Johanna Kantelhardt, Martin-Luther-University Halle-Wittenberg, Halle, Germany; Shahinaz Bedri, Weill Cornell Medicine-Qatar, Doha, Qatar; and Steffen Hauptmann, Maastricht University Medical Centre, Maastricht, the Netherlands.
Nada Suliman Haj MukhtarAsmerom Tesfamariam Sengal, Nada Suliman Haj Mukhtar, Ahmed Mohammed Elhaj, and Ahmed Abdalla Mohamedani, University of Gezira, Gezira, Sudan; Asmerom Tesfamariam Sengal, Orotta School of Medicine and Dentistry, Asmara, Eritrea; Martina Vetter, Christoph Thomssen, Claudia Wickenhauser, and Eva Johanna Kantelhardt, Martin-Luther-University Halle-Wittenberg, Halle, Germany; Shahinaz Bedri, Weill Cornell Medicine-Qatar, Doha, Qatar; and Steffen Hauptmann, Maastricht University Medical Centre, Maastricht, the Netherlands.
Martina VetterAsmerom Tesfamariam Sengal, Nada Suliman Haj Mukhtar, Ahmed Mohammed Elhaj, and Ahmed Abdalla Mohamedani, University of Gezira, Gezira, Sudan; Asmerom Tesfamariam Sengal, Orotta School of Medicine and Dentistry, Asmara, Eritrea; Martina Vetter, Christoph Thomssen, Claudia Wickenhauser, and Eva Johanna Kantelhardt, Martin-Luther-University Halle-Wittenberg, Halle, Germany; Shahinaz Bedri, Weill Cornell Medicine-Qatar, Doha, Qatar; and Steffen Hauptmann, Maastricht University Medical Centre, Maastricht, the Netherlands.
Ahmed Mohammed ElhajAsmerom Tesfamariam Sengal, Nada Suliman Haj Mukhtar, Ahmed Mohammed Elhaj, and Ahmed Abdalla Mohamedani, University of Gezira, Gezira, Sudan; Asmerom Tesfamariam Sengal, Orotta School of Medicine and Dentistry, Asmara, Eritrea; Martina Vetter, Christoph Thomssen, Claudia Wickenhauser, and Eva Johanna Kantelhardt, Martin-Luther-University Halle-Wittenberg, Halle, Germany; Shahinaz Bedri, Weill Cornell Medicine-Qatar, Doha, Qatar; and Steffen Hauptmann, Maastricht University Medical Centre, Maastricht, the Netherlands.
Shahinaz BedriAsmerom Tesfamariam Sengal, Nada Suliman Haj Mukhtar, Ahmed Mohammed Elhaj, and Ahmed Abdalla Mohamedani, University of Gezira, Gezira, Sudan; Asmerom Tesfamariam Sengal, Orotta School of Medicine and Dentistry, Asmara, Eritrea; Martina Vetter, Christoph Thomssen, Claudia Wickenhauser, and Eva Johanna Kantelhardt, Martin-Luther-University Halle-Wittenberg, Halle, Germany; Shahinaz Bedri, Weill Cornell Medicine-Qatar, Doha, Qatar; and Steffen Hauptmann, Maastricht University Medical Centre, Maastricht, the Netherlands.
Steffen HauptmannAsmerom Tesfamariam Sengal, Nada Suliman Haj Mukhtar, Ahmed Mohammed Elhaj, and Ahmed Abdalla Mohamedani, University of Gezira, Gezira, Sudan; Asmerom Tesfamariam Sengal, Orotta School of Medicine and Dentistry, Asmara, Eritrea; Martina Vetter, Christoph Thomssen, Claudia Wickenhauser, and Eva Johanna Kantelhardt, Martin-Luther-University Halle-Wittenberg, Halle, Germany; Shahinaz Bedri, Weill Cornell Medicine-Qatar, Doha, Qatar; and Steffen Hauptmann, Maastricht University Medical Centre, Maastricht, the Netherlands.
Christoph ThomssenAsmerom Tesfamariam Sengal, Nada Suliman Haj Mukhtar, Ahmed Mohammed Elhaj, and Ahmed Abdalla Mohamedani, University of Gezira, Gezira, Sudan; Asmerom Tesfamariam Sengal, Orotta School of Medicine and Dentistry, Asmara, Eritrea; Martina Vetter, Christoph Thomssen, Claudia Wickenhauser, and Eva Johanna Kantelhardt, Martin-Luther-University Halle-Wittenberg, Halle, Germany; Shahinaz Bedri, Weill Cornell Medicine-Qatar, Doha, Qatar; and Steffen Hauptmann, Maastricht University Medical Centre, Maastricht, the Netherlands.
Ahmed Abdalla MohamedaniAsmerom Tesfamariam Sengal, Nada Suliman Haj Mukhtar, Ahmed Mohammed Elhaj, and Ahmed Abdalla Mohamedani, University of Gezira, Gezira, Sudan; Asmerom Tesfamariam Sengal, Orotta School of Medicine and Dentistry, Asmara, Eritrea; Martina Vetter, Christoph Thomssen, Claudia Wickenhauser, and Eva Johanna Kantelhardt, Martin-Luther-University Halle-Wittenberg, Halle, Germany; Shahinaz Bedri, Weill Cornell Medicine-Qatar, Doha, Qatar; and Steffen Hauptmann, Maastricht University Medical Centre, Maastricht, the Netherlands.
Claudia WickenhauserAsmerom Tesfamariam Sengal, Nada Suliman Haj Mukhtar, Ahmed Mohammed Elhaj, and Ahmed Abdalla Mohamedani, University of Gezira, Gezira, Sudan; Asmerom Tesfamariam Sengal, Orotta School of Medicine and Dentistry, Asmara, Eritrea; Martina Vetter, Christoph Thomssen, Claudia Wickenhauser, and Eva Johanna Kantelhardt, Martin-Luther-University Halle-Wittenberg, Halle, Germany; Shahinaz Bedri, Weill Cornell Medicine-Qatar, Doha, Qatar; and Steffen Hauptmann, Maastricht University Medical Centre, Maastricht, the Netherlands.
Eva Johanna KantelhardtAsmerom Tesfamariam Sengal, Nada Suliman Haj Mukhtar, Ahmed Mohammed Elhaj, and Ahmed Abdalla Mohamedani, University of Gezira, Gezira, Sudan; Asmerom Tesfamariam Sengal, Orotta School of Medicine and Dentistry, Asmara, Eritrea; Martina Vetter, Christoph Thomssen, Claudia Wickenhauser, and Eva Johanna Kantelhardt, Martin-Luther-University Halle-Wittenberg, Halle, Germany; Shahinaz Bedri, Weill Cornell Medicine-Qatar, Doha, Qatar; and Steffen Hauptmann, Maastricht University Medical Centre, Maastricht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe objective of this study was to compare tumor characteristics, biomarkers, and surrogate subtypes of breast cancer between Sudanese and German women.

methodsTumor characteristics and immunohistochemistry markers (estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor 2 [HER2]) were collected from the routine assessment of consecutive patients with invasive breast cancer diagnosed from 2010 to 2015 (Gezira University Pathology Laboratory, Gezira, Sudan) and from 1999 to 2013 (Breast Centre, Martin-Luther-University, Halle, Germany).

resultsA total of 2,492 patients (German [n = 1,932] and Sudanese [n = 560]) were included. Age at diagnosis ranged from 20 to 94 years. Sudanese women were, on average, 10 years younger than German women, with a mean (± standard deviation) age of 48.8 (13.5) and 58.6 (12.4) years, respectively. The Sudanese women had a higher grade, larger tumor, and more lymph node positivity compared with German women. ER-, PR-, and HER2-negative proportions were 55%, 61.8%, and 71.3%, respectively, for Sudanese women versus 22.7%, 32.3%, and 82.5%, respectively, for German women. The triple-negative subtype was more prevalent in Sudanese women (34.5%) than in German women (14.2%). The strongest factor associated with ER-negative disease was grade III (odds ratio, 19.6; 95% CI 11.6 to 33.4; P < .001). Sudanese patients were at higher risk for ER-negative breast cancer, with an odds ratio of 2.01 ( P = .001; adjusted for age, size, nodal status, histologic type, and grade). Stratified by grade, the influence of origin was observed in grade I and grade II tumors, but not in grade III tumors.

conclusionSudanese women had more aggressive tumor characteristics and unfavorable prognostic biomarkers. After adjustment, Sudanese origin was still associated with hormone receptor-negative disease, especially in grade I and II tumors. These findings suggest differences in tumor biology among these ethnic groups.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsCohort StudiesErb-b2 Receptor Tyrosine KinasesFemaleGermanyHospitals, UniversityHumansMiddle AgedNeoplasm GradingReceptors, EstrogenReceptors, ProgesteroneSudanBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID30241184
PMCPMC6180747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.